BIOSYNEX (ALBIO.PA) Stock Price, Quote, News and Overview
EPA:ALBIO - Euronext Paris - Matif - FR0011005933 - Common Stock - Currency: EUR
ALBIO.PA Quote, Performance and Key Statistics
EPA:ALBIO (3/7/2025, 7:00:00 PM)
1.612
-0.08 (-4.5%)
The current stock price of ALBIO.PA is 1.612 EUR. In the past month the price increased by 36.61%. In the past year, price decreased by -72.06%.
ALBIO.PA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABL.DE | ABBOTT LABORATORIES | 29.15 | 217.38B | ||
| IUI1.DE | INTUITIVE SURGICAL INC | 69.31 | 166.86B | ||
| BSX.DE | BOSTON SCIENTIFIC CORP | 39.18 | 133.56B | ||
| 1BSX.MI | BOSTON SCIENTIFIC CORP | 39.52 | 133.38B | ||
| 1MDT.MI | MEDTRONIC PLC | 17.48 | 113.17B | ||
| 2M6.DE | MEDTRONIC PLC | 17.56 | 110.81B | ||
| 1SHL.MI | SIEMENS HEALTHINEERS AG | 25.27 | 60.49B | ||
| BOX.DE | BECTON DICKINSON AND CO | 16.4 | 60.33B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 23.49 | 59.08B | ||
| 1EW.MI | EDWARDS LIFESCIENCES CORP | 26.07 | 39.21B | ||
| EWL.DE | EDWARDS LIFESCIENCES CORP | 26.65 | 37.76B | ||
| DC4.DE | DEXCOM INC | 48.5 | 28.81B |
Related stock screener links
About ALBIO.PA
Company Profile
Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 521 full-time employees. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.
Company Info
BIOSYNEX
22 Boulevard Sebastien Brant
Illkirch-Graffenstaden GRAND EST FR
Employees: 569
Company Website: https://www.biosynex.com
Investor Relations: https://www.biosynex.com/business-contact/?lang=en
Phone: 33388787887
BIOSYNEX / ALBIO.PA FAQ
What is the stock price of BIOSYNEX today?
The current stock price of ALBIO.PA is 1.612 EUR. The price decreased by -4.5% in the last trading session.
What is the ticker symbol for BIOSYNEX stock?
The exchange symbol of BIOSYNEX is ALBIO and it is listed on the Euronext Paris - Matif exchange.
On which exchange is ALBIO.PA stock listed?
ALBIO.PA stock is listed on the Euronext Paris - Matif exchange.
What is the price forecast or stock price prediction for BIOSYNEX stock?
9 analysts have analysed ALBIO.PA and the average price target is 12.85 EUR. This implies a price increase of 697.27% is expected in the next year compared to the current price of 1.612. Check the BIOSYNEX stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOSYNEX worth?
BIOSYNEX (ALBIO.PA) has a market capitalization of 30.23M EUR. This makes ALBIO.PA a Nano Cap stock.
How many employees does BIOSYNEX have?
BIOSYNEX (ALBIO.PA) currently has 569 employees.
What are the support and resistance levels for BIOSYNEX (ALBIO.PA) stock?
BIOSYNEX (ALBIO.PA) has a support level at 1.21 and a resistance level at 1.72. Check the full technical report for a detailed analysis of ALBIO.PA support and resistance levels.
Is BIOSYNEX (ALBIO.PA) expected to grow?
The Revenue of BIOSYNEX (ALBIO.PA) is expected to grow by 23.98% in the next year. Check the estimates tab for more information on the ALBIO.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOSYNEX (ALBIO.PA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALBIO.PA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALBIO.PA, evaluating the profitability, health, valuation and growth aspects
- BIOSYNEX (ALBIO.PA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOSYNEX (ALBIO.PA) Sales and EPS estimates to see what analysts future expectations are.
- BIOSYNEX (ALBIO.PA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOSYNEX (ALBIO.PA) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOSYNEX (ALBIO.PA) Stock Chart to make your own analysis
- BIOSYNEX (ALBIO.PA) Latest news and press-releases to stay up to date.
Does BIOSYNEX (ALBIO.PA) stock pay dividends?
ALBIO.PA does not pay a dividend.
What is the Price/Earnings (PE) ratio of BIOSYNEX (ALBIO.PA)?
BIOSYNEX (ALBIO.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.05).
ALBIO.PA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ALBIO.PA. When comparing the yearly performance of all stocks, ALBIO.PA is a bad performer in the overall market: 97.46% of all stocks are doing better.
ALBIO.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALBIO.PA. ALBIO.PA may be in some trouble as it scores bad on both profitability and health.
ALBIO.PA Financial Highlights
Over the last trailing twelve months ALBIO.PA reported a non-GAAP Earnings per Share(EPS) of -3.05. The EPS increased by 0.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.5% | ||
| ROE | -37.41% | ||
| Debt/Equity | 0.12 |
ALBIO.PA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to ALBIO.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 103.92% and a revenue growth 23.98% for ALBIO.PA